Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.
Industry, Sector and Symbol
Stock Exchange TSE
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolTSE:VRX
CUSIPN/A
Phone+1-514-7446792
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins58.58%
Return on Equity112.73%
Return on Assets12.76%
Miscellaneous
EmployeesN/A
Outstanding Shares349,299,000
Market CapC$7.69 billion
Valeant Pharmaceuticals Intl (TSE:VRX) Frequently Asked Questions
What is Valeant Pharmaceuticals Intl's stock symbol?
Valeant Pharmaceuticals Intl trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VRX."
What price target have analysts set for VRX?
2 brokerages have issued twelve-month price objectives for Valeant Pharmaceuticals Intl's shares. Their predictions range from C$25.00 to C$25.50. On average, they anticipate Valeant Pharmaceuticals Intl's stock price to reach C$25.25 in the next year. This suggests that the stock has a possible downside of 16.6%. View Analyst Price Targets for Valeant Pharmaceuticals Intl.
What is the consensus analysts' recommendation for Valeant Pharmaceuticals Intl?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Valeant Pharmaceuticals Intl in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Valeant Pharmaceuticals Intl.
Who are some of Valeant Pharmaceuticals Intl's key competitors?
Some companies that are related to Valeant Pharmaceuticals Intl include MERCK KGAA/S (MKKGY), Merck KGaA (MRK), Canopy Growth (WEED), Aurora Cannabis (ACB), STADA Arzneimittel (SAZ), Hikma Pharmaceuticals (HKMPY), Hikma Pharmaceuticals (HIK), Aphria (APH), MedReleaf (LEAF), Knight Therapeutics (KHTRF), Hydropothecary (THCX), OrganiGram (OGI), Supreme Cannabis (FIRE), Weed (BUDZ) and OrganiGram (OGRMF).
Who are Valeant Pharmaceuticals Intl's key executives?
Valeant Pharmaceuticals Intl's management team includes the folowing people:
- Mr. Joseph C. Papa, CEO & Chairman (Age 63)
- Mr. Paul S. Herendeen, Exec. VP & CFO (Age 62)
- Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 53)
- Mr. Thomas J. Appio, Exec. VP & Group Chairman of International (Age 56)
- Mr. William D. Humphries, Exec. VP & Group Chairman of Dermatology (Age 52)
Has Valeant Pharmaceuticals Intl been receiving favorable news coverage?
Media coverage about VRX stock has trended somewhat positive recently, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Valeant Pharmaceuticals Intl earned a coverage optimism score of 0.18 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Valeant Pharmaceuticals Intl.
How do I buy shares of Valeant Pharmaceuticals Intl?
Shares of VRX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Valeant Pharmaceuticals Intl's stock price today?
One share of VRX stock can currently be purchased for approximately C$30.27.
How big of a company is Valeant Pharmaceuticals Intl?
Valeant Pharmaceuticals Intl has a market capitalization of C$7.69 billion.
How can I contact Valeant Pharmaceuticals Intl?
Valeant Pharmaceuticals Intl's mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-7446792.
MarketBeat Community Rating for Valeant Pharmaceuticals Intl (TSE VRX)
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe VRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
